October 28, 2021
Authored and Edited by Kelly S. Horn; Sydney R. Kestle; Elizabeth D. Ferrill
In In re: SurgiSil, L.L.P., No. 2020-1940 (Fed. Cir. Oct. 4, 2021), the Federal Circuit reversed the Board’s decision affirming an examiner’s rejection of Surgisil’s design patent application.
Surgisil’s application claims “an ornamental design for a lip implant as shown and described” in the below figure:

The examiner rejected the sole claim as anticipated by a catalog disclosing an “art tool called a stump.” The stump is made of “tightly spiral-wound, soft gray paper,” is used “for smoothing and blending large areas of pastel or charcoal,” and is shown below:

The Board affirmed the rejection, finding the differences in shape between the claimed design and the stump to be minor. It rejected Surgisil’s argument that the catalog could not anticipate the claim because it disclosed a “very different” article of manufacture than a lip implant and, in the Board’s view, “it is appropriate to ignore the identification of the article of manufacture in the claim language.”
The Federal Circuit reversed. It held that “[a] design claim is limited to the article of manufacture identified in the claim.” Because the claim recited a “lip implant,” and the figures depicted in the application illustrate a lip implant, the Court held “the claim is limited to lip implants and does not cover other articles of manufacture.” The Board’s rejection based on prior art showing an art tool was improper despite the similar appearance between the two.
Copyright © 2021 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Panel Discussion
May 5, 2026
London
At the PTAB Blog
Revvo‑lution in Discretionary Denial: Claim Construction Consistency Takes Center Stage
April 28, 2026
Articles
Unpacking Squires’ Recent Discretionary Denial Guidance Focusing on American Manufacturing
April 24, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.